Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use

• Status: Completed
• Trial end date: 2018-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to evaluate the influence of genetic polymorphisms of OCTN1 and OCT2 and other possible covariates on the kinetic disposition of GAB in patients undergoing GAB chronic treatment. Thus, patients treated with GAB, for at least one week, are being investigated.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: São Paulo State University
• Collaborator: University of Sao Paulo
• Treatments: Gabapentin; gamma-Aminobutyric Acid

Criteria

Inclusion Criteria:

• Patients with 18 years old or older, both gender.

• Patients undergoing chronic use of gabapentin (at least one week).

Exclusion Criteria:

• Pregnant and lactating patients.

• Patients who were in use of OCT2 and OCTN1 inhibitors.

• Patients who disagree to continue the study.